SCHEMBL14076723

SCHEMBL14076723

CCOc1cc(CNC)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.43
LOX P28300 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PRMT6 Q96LA8 3/20 0.40
EPHX2 P34913 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ACACB O00763 4/20 0.38
IGF1R P08069 1/20 0.37
ADRB2 P07550 1/20 0.37
HTT P42858 1/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 1/20 0.35
KLKB1 P03952 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178404 0.84 LOXL2 (0.62) LOXL2LOXPRMT6EPHX2ACACB
Hydrochloric Acid SCHEMBL22164586 0.82 LOX (0.61) LOXL2LOXPRMT6EPHX2ADRB2
SCHEMBL13226976 0.81 NOS3 (0.53) LOXL2LOXSMN1; SMN2ACACBIGF1R
Hydrochloric Acid SCHEMBL30939095 0.79 LOXL2 (0.38) LOXL2LOXMEN1KMT2APRMT6
SCHEMBL31256818 0.78 LOXL2 (0.46) LOXL2LOXSMN1; SMN2ACACBIGF1R
SCHEMBL2940184 0.78 LOXL2 (0.46) LOXL2LOXSMN1; SMN2ACACBIGF1R
SCHEMBL134512 0.78 LOXL2 (0.46) LOXL2LOXMEN1KMT2ASMN1; SMN2
SCHEMBL2940362 0.78 RECQL (0.50) LOXL2LOXACACBIGF1RHTT
SCHEMBL4933505 0.78 LOXL2 (0.70) LOXL2LOXNOS3NOS1NOS2
SCHEMBL28718096 0.76 LOXL2 (0.49) LOXL2LOXSMN1; SMN2ACACBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 US disclosed
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2008-09-18 US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 US disclosed
US-7375222-B2 2,4,6-Triamino-1,3,5-triazine derivative ASTELLAS PHARMA INC. (JP) 2008-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227785-A1 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE KCNT1, KCNMA1, KCNJ2 LOXL2 3459/4885LOX 2762/4885MEN1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.